C4 Therapeutics, Inc.
CCCC · Price history
Price at last available close
$3.42
+$0.30 (+9.78%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About C4 Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins.
How they make money
C4 Therapeutics is a clinical-stage biopharmaceutical company that generates revenue primarily through research and development collaboration agreements. These agreements typically involve upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and potential future royalties from the commercialization of licensed therapeutic candidates.
Products & services
The company develops targeted protein degradation (TPD) therapeutics, including clinical-stage candidates such as cemsidomide (CFT7455) for multiple myeloma and CFT1946 for solid tumors, designed to destroy disease-causing proteins.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Biopharmaceutical and pharmaceutical companiesSource
Disclosed major customers
- Merck KGaASource
Customer concentration
For the year ended December 31, 2025, the company reported that a significant portion of its revenue was derived from a limited number of collaboration partners, including Merck KGaA.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for preclinical testing, clinical trial management, and the manufacturing of drug substances and products. Specific supplier names are not disclosed.Source
Business relationships & partnerships
- Merck KGaA — A strategic collaboration to discover and develop targeted protein degradation-based antibody drug conjugates (DACs).Source
Competitors
Strengths
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Diluted weighted-average shares increased 84.1% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
24
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
28
Poor
Financial Strength
47
Business Quality / Moat
0
Management
40
Growth Quality
23
Risk / Durability
27
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
30
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
39/100
Building Historical Record
Model Score 39/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for CCCC
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving CCCC's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can CCCC fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does CCCC's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for CCCC to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CCCC's current valuation?
Essential Investment Snapshot
Wall Street Score
24
Opportunity Score
30
Market Cap
$419.5M
P/E Ratio
-3.3
EPS
$-1.00
52-Week High
$5.17
52-Week Low
$1.69
Beta
2.94
Analyst Target
$10.00
Shares Outstanding
82.9M
Total Revenue
$35.0M
Total Debt
$56.9M
Dividend
No current dividend
Liquidation Value / Share
$2.98
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CCCC
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on CCCC.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary TORPEDO platform for targeted protein degradation.
- +Experienced management team and scientific leadership.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party collaborators and contract manufacturers.
- −Uncertainty regarding clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
24
Sep 14, 2026
Change
+0.2
points
Current Score
24
Oct 1, 2026
Category Changes
CCCC increased 0.2 points because overall fundamentals improved.
Projected Score
Projected Score
24
Projected Change
-0.4 points
Preliminary comparable-period financial changes suggest decline of approximately 0.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$3.41
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.0M | $35.9M | $35.6M | $20.8M | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.8M | $8.0M | $0.00 | $7.7M | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $33.2M | $28.0M | $35.6M | $13.0M | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $100.0M | $104.2M | $110.6M | $117.7M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $34.2M | $36.2M | $42.1M | $42.1M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $145.0M | $132.5M | $155.2M | $152.1M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$98.3M | -$102.9M | -$103.4M | -$122.1M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$111.8M | -$104.5M | -$119.6M | -$139.0M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $1.4M | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$101.3M | -$104.9M | -$105.2M | -$131.2M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $121K | $121K | $131K | $1.3M | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$101.4M | -$105.0M | -$105.3M | -$132.5M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.00 | $-1.27 | $-1.52 | $-2.67 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 131M | 82.89M | 69.37M | 49.64M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 131M | 82.89M | 69.37M | 49.64M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$6.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.18
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-9.6%
Cash Change
+0.6%
Margin Change
+46.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 2.8%. EPS declined 51.4%. Cash increased 0.6%. Total debt declined 9.6%. Net income margin improved by 46.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS)
Rumor Mill · CCCC
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial